Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Reprogramming of Tumor Stroma to Enhance Cancer Immunotherapy

Project description

Tumour mesenchymal cells: new targets for enhanced immunotherapy?

Tumours are surrounded by stroma, supportive tissue consisting of various cell types and extracellular matrix components. The interactions between cancer cells and the stroma can create a microenvironment that promotes tumour survival and resistance to treatments, making it an important focus for cancer research and potential therapeutic strategies. Recent findings have identified tumour-activated mesenchymal stromal cells (MSCs) as key factors that impede effective antitumour immunity. The ERC-funded REACT project aims to explore a novel strategy to target specific MSC populations within the tumour microenvironment and assess their synergistic effects with immunotherapies. Project findings are expected to enhance immunotherapy outcomes for solid tumours.

Objective

Cancer immunotherapies have shown impressive success in cancer treatment. However, these therapies are limited to certain type of cancers, and success rate is still low. In particular, certain types of solid tumors containing an abundant stroma, which represent a majority of epithelial derived cancer, respond very poorly to immunotherapies. In these tumors, a major challenge for the development of novel cancer immunotherapies is represented by the tumor microenvironment (TME), a highly hypoxic and immunosuppressive environment which prevents proper tumor infiltration and functioning of effector immune cells. Recent discoveries identified tumor-activated mesenchymal stromal cells (MSCs) developing within the TME, and showed that they represent a major brake for efficient antitumor immunity in solid tumors. In this project, we will investigate the potential of a novel approach and therapeutic avenue to target specific populations of MSCs within the TME, and determine the synergistic effect with immunotherapies to improve treatment efficacy in solid tumors. In the long term, this project aims at overcoming a major barrier in utilizing cancer immunotherapies in solid tumors.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-POC

See all projects funded under this call

Host institution

INSTITUT PASTEUR
Net EU contribution
€ 150 000,00
Address
RUE DU DOCTEUR ROUX 25-28
75724 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)